{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:45:22Z","timestamp":1761101122761},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[1989,4,1]],"date-time":"1989-04-01T00:00:00Z","timestamp":607392000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Toxicol Adverse Drug Exp"],"published-print":{"date-parts":[[1989,4]]},"DOI":"10.1007\/bf03259909","type":"journal-article","created":{"date-parts":[[2012,11,30]],"date-time":"2012-11-30T05:10:09Z","timestamp":1354252209000},"page":"144-152","source":"Crossref","is-referenced-by-count":14,"title":["Tolerability of Long Term Therapy with Enalapril Maleate in Patients Resistant to Other Therapies and Intolerant to Captopril"],"prefix":"10.1007","volume":"4","author":[{"given":"E. J.","family":"Rucinska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Small","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. S.","family":"Mulcahy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. L.","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. V.","family":"Rodel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. E.","family":"Rush","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. D.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. F.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. D.","family":"Irvin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,11,27]]},"reference":[{"key":"BF03259909_CR1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0140-6736(83)90020-X","volume":"2","author":"JN Barnes","year":"1983","unstructured":"Barnes JN, Davies ES, Gant CB. Rash, eosinophilia and hyperkalemia associated with enalapril. Lancet 2: 41\u201342, 1983","journal-title":"Lancet"},{"key":"BF03259909_CR2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/BF01725192","volume":"62","author":"H Cremer","year":"1984","unstructured":"Cremer H. Reproduceierbarkeit einer Captopril-indurizerten okuten Niereninsuffizienz durch Enalapril. Klinische Wochenschrift 62: 43\u201345, 1984","journal-title":"Klinische Wochenschrift"},{"key":"BF03259909_CR3","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJM198606263142602","volume":"314","author":"SH Croog","year":"1986","unstructured":"Croog SH, Levine S, Testa MA, Brown B, Bulpitt CJ, et al. The effects of antihypertensive therapy on the quality of life. New England Journal of Medicine 314: 1657\u20131664, 1986","journal-title":"New England Journal of Medicine"},{"key":"BF03259909_CR4","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1056\/NEJM198006193022501","volume":"302","author":"VJ Dzau","year":"1980","unstructured":"Dzau VJ, Colucci WS, Williams GH, Curfman G, Meggs L, et al. Sustained effectiveness of converting enzyme inhibition in patients with severe congestive heart failure. New England Journal of Medicine 302: 1373\u20131379, 1980","journal-title":"New England Journal of Medicine"},{"key":"BF03259909_CR5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0735-1097(85)80090-5","volume":"5","author":"JA Franciosa","year":"1985","unstructured":"Franciosa JA, Wilen MM, Jordan RA. Effects of enalapril, a new angiotensin-converting enzyme inhibitor, in a controlled trial in heart failure. Journal of the American College of Cardiology 5: 101\u2013107, 1985","journal-title":"Journal of the American College of Cardiology"},{"key":"BF03259909_CR6","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1001\/archinte.1984.00350190137023","volume":"144","author":"ED Frohlich","year":"1984","unstructured":"Frohlich ED, Cooper RA, Lewis EJ. Review of the overall experience of captopril in hypertension. Archives of Internal Medicine 144: 1441\u20131444, 1984","journal-title":"Archives of Internal Medicine"},{"issue":"4C","key":"BF03259909_CR7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/0002-9343(86)90945-9","volume":"81","author":"JD Irvin","year":"1986","unstructured":"Irvin JD, Viau JM. Safety profiles of the angiotensin converting enzyme inhibitors, captopril and enalapril. American Journal of Medicine 81(4C): 46\u201350, 1986","journal-title":"American Journal of Medicine"},{"key":"BF03259909_CR8","first-page":"218","volume":"129","author":"HJ Keim","year":"1987","unstructured":"Keim HJ, Beckers G. Medikamentos induzierter reizhusten: charakteristische nebenwirkung der hemmung des angiotensin-converting-enzyms (ACE). M:nchener Medizinische Wochenschrift 129: 218\u2013220, 1987","journal-title":"M:nchener Medizinische Wochenschrift"},{"key":"BF03259909_CR9","doi-asserted-by":"crossref","first-page":"616","DOI":"10.7326\/0003-4819-100-4-616_1","volume":"100","author":"SH Kubo","year":"1984","unstructured":"Kubo SH, Cody RJ. Enalapril, a rash, and captopril. Annals of Internal Medicine 100: 616, 1984","journal-title":"Annals of Internal Medicine"},{"key":"BF03259909_CR10","first-page":"205","volume":"39","author":"MC Laver","year":"1986","unstructured":"Laver MC, DeJong P, Russel J, Taylor RN, McCarthy EP. Ability of patients who have had previous captopril-induced agranulocytosis to tolerate enalapril. Clinical Pharmacology and Therapeutics 39: 205, 1986","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"BF03259909_CR11","first-page":"88","volume-title":"Statistical methods for survival data analysis","author":"ET Lee","year":"1980","unstructured":"Lee ET. Statistical methods for survival data analysis, pp. 88\u201396, Lifetime Learning Publications, Belmont, California, 1980"},{"key":"BF03259909_CR12","first-page":"719","volume":"22","author":"N Mantel","year":"1959","unstructured":"Mantel N, Haenszel W. Statistical aspects of the analyses of data from retrospective studies. Journal of the National Cancer Institute 22: 719\u2013748, 1959","journal-title":"Journal of the National Cancer Institute"},{"key":"BF03259909_CR13","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/00005344-198700003-00005","volume":"9","author":"MG Nicholls","year":"1987","unstructured":"Nicholls MG, Arakawa K. Angiotensin converting enzyme inhibitors in congestive heart failure. Journal of Cardiovascular Pharmacology 9: S19\u2013S21, 1987","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"1","key":"BF03259909_CR14","first-page":"179","volume":"2","author":"M Packer","year":"1986","unstructured":"Packer M, Kessler PD, Gottlieb SS. Adverse effects of converting enzyme inhibition in patients with severe congestive heart failure: pathophysiology and management. Postgraduate Medical Journal C2(1): 179\u2013182, 1986","journal-title":"Postgraduate Medical Journal C"},{"issue":"2","key":"BF03259909_CR15","first-page":"75","volume":"2","author":"P Sassano","year":"1984","unstructured":"Sassano P, Chatellier G, Amiot A-M, Alhenc-Geles F, Corvol P, et al. A double-blind randomized evaluation of converting enzyme inhibition as the first-step treatment of mild to moderate hypertension. Journal of Hypertension 2 (Suppl. 2): 75\u201380, 1984","journal-title":"Journal of Hypertension"},{"key":"BF03259909_CR16","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1161\/01.CIR.70.2.271","volume":"70","author":"DN Sharpe","year":"1984","unstructured":"Sharpe DN, Murphy J, Coxon J, Hannon SF. Enalapril in patients with chronic heart failure: a placebo-controlled, randomized, double-blind study. Circulation 70: 271\u2013278, 1984","journal-title":"Circulation"},{"key":"BF03259909_CR17","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/art.1780270716","volume":"27","author":"CD Smith","year":"1984","unstructured":"Smith CD, Smith RD, Korn JH. Hypertensive crisis in systemic sclerosis: treatment with the new oral angiotensin converting enzyme inhibitor MK-421 (enalapril) in captopril-intolerant patients. Arthritis and Rheumatism 27: 826\u2013828, 1984a","journal-title":"Arthritis and Rheumatism"},{"issue":"2","key":"BF03259909_CR18","first-page":"113","volume":"2","author":"WM Smith","year":"1984","unstructured":"Smith WM, Kulaga SF, Moncloa F, Pingeon R, Walker JF. Overall tolerance and safety of enalapril. Journal of Hypertension 2 (Suppl. 2): 113\u2013117, 1984b","journal-title":"Journal of Hypertension"},{"key":"BF03259909_CR19","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1161\/01.CIR.45.5.991","volume":"45","author":"VA Cooperative Study Group","year":"1972","unstructured":"VA Cooperative Study Group. Effects of treatment on morbidity in hypertension, III: influence of age, diastolic pressure, and prior cardiovascular disease; further analysis of side effects. Circulation 45: 991\u20131004, 1972","journal-title":"Circulation"},{"key":"BF03259909_CR20","first-page":"1","volume":"2","author":"PH Vlasses","year":"1981","unstructured":"Vlasses PH, Ferguson RK, Chatterjee K. Captopril: clinical pharmacology and benefit-to-risk ratio in hypertension and congestive heart failure. Pharmacology 2: 1, 1981","journal-title":"Pharmacology"},{"key":"BF03259909_CR21","doi-asserted-by":"crossref","first-page":"030","DOI":"10.1177\/003693308603100107","volume":"31","author":"EJ Webb","year":"1986","unstructured":"Webb EJ, Atkinson AB. Enalapril following captopril-induced nephrotic syndrome. Scottish Medical Journal 31: 030\u2013032, 1986","journal-title":"Scottish Medical Journal"},{"key":"BF03259909_CR22","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/bmj.294.6564.91","volume":"294","author":"SM Wood","year":"1987","unstructured":"Wood SM, Mann RD, Rawlins MD. Angio-edema and urticaria associated with angiotensin converting enzyme inhibitors. British Medical Journal 294: 91\u201392, 1987","journal-title":"British Medical Journal"},{"key":"BF03259909_CR23","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1097\/00005344-198700003-00002","volume":"9","author":"A Zanchetti","year":"1987","unstructured":"Zanchetti A. Angiotensin converting enzyme inhibitors in essential hypertension. Journal of Cardiovascular Pharmacology 9: S2\u2013S5, 1987","journal-title":"Journal of Cardiovascular Pharmacology"}],"container-title":["Medical Toxicology and Adverse Drug Experience"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03259909.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03259909\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03259909","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T01:34:08Z","timestamp":1558488848000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03259909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1989,4]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1989,4]]}},"alternative-id":["BF03259909"],"URL":"https:\/\/doi.org\/10.1007\/bf03259909","relation":{},"ISSN":["0113-5244","1179-1942"],"issn-type":[{"value":"0113-5244","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[1989,4]]}}}